Sargent Investment Group LLC Makes New Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

Sargent Investment Group LLC bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 5,054 shares of the biopharmaceutical company’s stock, valued at approximately $455,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in GILD. State Street Corp raised its holdings in shares of Gilead Sciences by 1.4% during the third quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company’s stock valued at $5,044,795,000 after acquiring an additional 841,776 shares during the period. Wellington Management Group LLP grew its position in Gilead Sciences by 50.9% in the third quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock worth $2,900,921,000 after acquiring an additional 11,665,593 shares in the last quarter. FMR LLC grew its position in Gilead Sciences by 79.4% in the third quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock worth $2,780,329,000 after acquiring an additional 14,680,161 shares in the last quarter. Geode Capital Management LLC grew its position in Gilead Sciences by 2.1% in the third quarter. Geode Capital Management LLC now owns 27,540,870 shares of the biopharmaceutical company’s stock worth $2,302,119,000 after acquiring an additional 574,421 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Gilead Sciences by 3.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 7,752,975 shares of the biopharmaceutical company’s stock worth $650,009,000 after buying an additional 224,960 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on GILD shares. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $84.00 price objective on shares of Gilead Sciences in a report on Monday. Wolfe Research initiated coverage on shares of Gilead Sciences in a research note on Friday, November 15th. They issued an “outperform” rating and a $110.00 price objective for the company. Oppenheimer increased their price objective on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. Cantor Fitzgerald reiterated a “neutral” rating and set a $80.00 target price on shares of Gilead Sciences in a research report on Wednesday, December 11th. Finally, Piper Sandler increased their target price on shares of Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Eleven research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $98.39.

Insider Activity at Gilead Sciences

In other news, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the sale, the director now owns 8,920 shares of the company’s stock, valued at approximately $815,198.80. This trade represents a 43.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 142,180 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $97.22, for a total value of $13,822,739.60. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at approximately $12,626,253.06. This trade represents a 52.26 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 572,824 shares of company stock valued at $53,611,715. 0.29% of the stock is owned by corporate insiders.

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD opened at $99.65 on Thursday. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $100.51. The company has a market capitalization of $124.19 billion, a price-to-earnings ratio of 1,107.22, a P/E/G ratio of 1.37 and a beta of 0.18. The firm’s 50 day simple moving average is $92.71 and its 200 day simple moving average is $86.32.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. During the same period last year, the company earned $2.29 earnings per share. The firm’s revenue was up 7.0% compared to the same quarter last year. As a group, sell-side analysts forecast that Gilead Sciences, Inc. will post 4.34 earnings per share for the current year.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.